Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Mindray Medical’s Q3 Financial Report Disappoints

publication date: Nov 7, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Mindray Medical reported that its Q2 revenues rose 18% to $257 million, with non-GAAP net income up an equal 18% at $50 million. Unfortunately, those results were below analysts’ estimates. Also, a $10 million charge took EBITDA and net income lower than the prior year’s similar period. The charge derives from a pricing dispute with a supplier over costs for components of patient monitors sold in the US. More details....

Stock Symbol: (NYSE: MR)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors